Ignite Creation Date:
2024-05-05 @ 9:57 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00003820
Status:
COMPLETED
Last Update Posted:
2017-04-20
First Post:
1999-11-01
Brief Title:
Rituximab in Treating Patients With Hodgkins Lymphoma
Sponsor:
Ranjana Advani
Organization:
Stanford University
Study Overview
Official Title:
Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkins Disease
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkins lymphoma
Detailed Description:
This study will evaluate the partial complete and overall response rates to rituximab of subjects with lymphocyte-predominant Hodgkins lymphoma Subjects will receive rituximab by IV infusion over several hours once a week for 4 weeks followed by maintenance therapy as repeat course of the same dose and schedule rituximab at 6 12 and 18 months
This was a single-arm study with multiple treatment periods added by amendment ie Secondary Group with results reported by treatment period As this was always considered a single-arm study there was no intent to report the results for the initial treatment period separately as the Initial Group vs the Secondary Group
This was a single-arm study with multiple treatment periods added by amendment ie Secondary Group with results reported by treatment period As this was always considered a single-arm study there was no intent to report the results for the initial treatment period separately as the Initial Group vs the Secondary Group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LYMHD0003 | OTHER | OnCore | None |
| 75967 | OTHER | None | None |
| U2082N | None | None | None |